Wall Street analysts forecast that Cooper Companies Inc (NYSE:COO) will report sales of $645.40 million for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Cooper Companies’ earnings. The lowest sales estimate is $640.70 million and the highest is $656.30 million. Cooper Companies reported sales of $561.50 million during the same quarter last year, which indicates a positive year-over-year growth rate of 14.9%. The firm is expected to report its next earnings results after the market closes on Thursday, December 6th.
On average, analysts expect that Cooper Companies will report full-year sales of $2.53 billion for the current fiscal year, with estimates ranging from $2.52 billion to $2.53 billion. For the next financial year, analysts forecast that the firm will post sales of $2.68 billion, with estimates ranging from $2.67 billion to $2.70 billion. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Cooper Companies.
Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, August 30th. The medical device company reported $3.00 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.07 by ($0.07). Cooper Companies had a net margin of 5.23% and a return on equity of 17.53%. The company had revenue of $660.00 million for the quarter, compared to the consensus estimate of $653.44 million.
Several equities analysts have weighed in on COO shares. Zacks Investment Research lowered Cooper Companies from a “hold” rating to a “sell” rating in a report on Monday, September 3rd. BMO Capital Markets raised their target price on Cooper Companies from $280.00 to $285.00 and gave the company an “outperform” rating in a report on Friday, August 31st. Raymond James raised their target price on Cooper Companies from $270.00 to $300.00 and gave the company an “outperform” rating in a report on Friday, September 21st. Oppenheimer set a $270.00 target price on Cooper Companies and gave the company a “hold” rating in a report on Friday, August 31st. Finally, ValuEngine upgraded Cooper Companies from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Cooper Companies presently has an average rating of “Buy” and an average target price of $274.25.
In other news, Director A Thomas Bender sold 7,150 shares of the firm’s stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $269.36, for a total value of $1,925,924.00. Following the sale, the director now directly owns 18,355 shares of the company’s stock, valued at $4,944,102.80. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Agostino Ricupati sold 1,575 shares of the firm’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $261.56, for a total value of $411,957.00. Following the completion of the sale, the senior vice president now directly owns 1,897 shares in the company, valued at $496,179.32. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,809 shares of company stock worth $20,740,667. 1.60% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the company. Frontier Capital Management Co. LLC grew its position in shares of Cooper Companies by 18.0% in the second quarter. Frontier Capital Management Co. LLC now owns 825,561 shares of the medical device company’s stock valued at $194,378,000 after purchasing an additional 126,101 shares during the last quarter. Andra AP fonden acquired a new stake in Cooper Companies during the second quarter worth about $2,072,000. We Are One Seven LLC acquired a new stake in Cooper Companies during the third quarter worth about $394,000. Raymond James Trust N.A. acquired a new stake in Cooper Companies during the third quarter worth about $214,000. Finally, Handelsinvest Investeringsforvaltning grew its position in Cooper Companies by 23.1% during the third quarter. Handelsinvest Investeringsforvaltning now owns 51,696 shares of the medical device company’s stock worth $14,327,000 after buying an additional 9,700 shares in the last quarter. 97.07% of the stock is currently owned by institutional investors.
NYSE COO opened at $267.80 on Friday. Cooper Companies has a fifty-two week low of $216.47 and a fifty-two week high of $280.10. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 2.58. The stock has a market cap of $12.76 billion, a price-to-earnings ratio of 27.61, a P/E/G ratio of 1.97 and a beta of 0.75.
About Cooper Companies
The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.
Recommended Story: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.